GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nuo Therapeutics AURX · USD

N/A · US listing · 🇺🇸 United States

Compare

1.07

-15.08%

Close of 5 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$3.3m

FY2016FY2025

Net income

−$2.5m

FY2016FY2025

Free cash flow

−$1.1m

FY2016FY2025

Shareholders' equity

−$956,559

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$3.3m$1.4m$608,525$112,250—$4,900$146,177$1.4m$721,045$2.2m
Research and development——————$181,185$576,192$1.3m$1.6m
Operating income−$2.5m−$2.5m−$3.2m−$3.3m−$90,670−$378,059−$969,198−$1.5m−$6.2m−$7.8m
Net income−$2.5m−$2.3m−$3.2m−$3.2m−$90,670−$90,870−$1.2m−$1.5m−$15.0m$22.5m
Diluted earnings per share-0.05-0.05-0.07-0.08-0.00-0.00-0.05-0.06-0.660.22

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$1.8m$1.2m$1.9m$3.0m$149,930$153,085$157,264$975,497$1.4m$14.1m
Total liabilities$2.8m$675,796$838,732$856,022$672,467$668,871$666,504$1.1m$941,168$1.6m
Debt$500,000——————$309,010——
Shareholders' equity−$956,559$513,712$1.0m$2.2m−$522,537−$515,786−$509,240−$81,987$482,871$12.5m
Shares outstanding48m47m44m42m37m37m24m24m23m104m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$864,971−$2.2m−$3.2m−$3.7m−$119,955−$53,821−$921,674−$874,388−$4.9m−$10.9m
Capital spending−$274,756−$154,962−$7,244−$59,992−$59,992−$59,992−$59,992———
Free cash flow−$1.1m−$2.4m−$3.2m−$3.8m−$179,947−$113,813−$981,666−$874,388−$4.9m−$10.9m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$1.8m$1.3m$1.1m$1.0m$700,202$484,381$394,872$370,951
Operating income−$163,535−$443,184−$579,338−$540,100−$652,022−$744,533−$629,234−$577,373
Net income−$277,601−$618,466−$578,480−$537,900−$649,689−$746,128−$496,666−$578,167
Diluted earnings per share-0.01-0.01-0.01-0.01-0.01-0.02-0.01-0.01
Total assets$2.6m$1.9m$1.8m—$1.4m$1.1m$1.2m$1.7m
Debt$1.8m$1.0m$500,000—————
Shareholders' equity−$1.5m−$1.4m−$956,559—−$824,562−$213,073$513,712$890,387

Growth per year

Compound annual rate

3 years5 years10 years
Revenue209.1%268.1%-11.7%
Operating income-8.8%46.1%-15.4%
Net income-7.5%94.2%-26.3%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-106.3%-212.3%——
Net margin-103.4%-207.0%——

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2020
Price to earnings-37.9-28.2-4.5-7.0-0.0
Price to sales28.748.023.6198.10.6

Share price return

Finished calendar years

202520242023202220212020201920182017
Return59%311%-40%17577%35570%2839%1051%28575%17%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.